Severity index for rheumatoid arthritis and its association with health care costs and biologic therapy use in Turkey

Health Economics Review

Volumn 3, Issue 1, 2013, Pages 1-7

  Baser, Onur ^a,b   Baser, Erdem ^b   Altinbas, Akif ^c   Burkan, Abdulkadir ^d  

^a UNIVERSITY OF MICHIGAN   (United States)

^b STATINMED RESEARCH   (United States)

^c Diskapi Y Beyazit Training and Research Hospital   (Turkey)

^d Social Security Institution   (Turkey)

Author keywords

Medical costs; Outcomes research; Real world data analysis; Rheumatoid arthritis; Severity index

Indexed keywords

ADULT; AGED; ARTICLE; BIOLOGICAL THERAPY; COST BENEFIT ANALYSIS; DISEASE SEVERITY; FOLLOW UP; FUNCTIONAL STATUS; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OUTCOME ASSESSMENT; PATIENT IDENTIFICATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SEVERITY INDEX FOR RHEUMATOID ARTHRITIS; TURKEY (REPUBLIC);

EID: 84971237991     PISSN: None     EISSN: 21911991     Source Type: Journal    
DOI: 10.1186/2191-1991-3-5     Document Type: Article

References (29)

1. Markenson JA: Worldwide trends in the socioeconomic impact and long-term prognosis of rheumatoid arthritis. Semin Arthritis Rheum 1991, 21(2 Suppl 1):4-12.
2. Lundkvist J, Kastäng F, Kobelt G: The burden of rheumatoid arthritis and access to treatment: health burden and costs. Eur J Health Econ 2008, 8(Suppl 2):s49-s60.
3. Alarcón GS: Epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am 1995, 21(3):589-604.
4. Rasch EK, Hirsch R, Paulose-Ram R, Hochberg MC: Prevalence of rheumatoid arthritis in persons 60 years of age and older in the United States: effect of different methods of case classification. Arthritis Rheum 2003, 48(4):917-926.
5. Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, Liang MH, Kremers HM, Mayes MD, Merkel PA, Pillemer SR, Reveille JD, Stone JH, National Arthritis Data Workgroup: Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part I. Arthritis Rheum 2008, 58(1):15-25.
6. Jönsson B, Kobelt G, Smolen J: The burden of rheumatoid arthritis and access to treatment: uptake of new therapies. Eur J Health Econ 2008, 8(Suppl 2):s61-s86.
7. Kremer JM, Lee JK: The safety and efficacy of the use of methotrexate in long term therapy for rheumatoid arthritis. Arthritis Rheum 1986, 29(7):822-831.
8. Kahlenberg JM, Fox DA: Advances in the medical treatment of rheumatoid arthritis. Hand Clin 2011, 27(1):11-20.
9. Scott D, Kingsley G: Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med 2006, 355(7):704-712.
10. Yazici Y, Shi N, John A: Utilization of biologic agents in rheumatoid arthritis in the United States: analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapy. Bull NYU Hosp Jt Dis 2008, 66(2):77-85.
11. Birnbaum H, Pike C, Kaufman R, Marynchenko M, Kidolezi Y, Cifaldi M: Societal cost of rheumatoid arthritis patients in the US. Curr Med Res Opin 2009, 26(1):77-90.
12. Clinical ACR: Guidelines Committee: Guidelines for the management of rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Arthritis Rheum 1996, 39(5):713-722.
13. Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, Heyse SP, Hirsch R, Hochberg MC, Hunder GG, Liang MH, Pillemer SR, Steen VD, Wolfe F: Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998, 41(5):778-799.
14. MacLean CH, Louie R, Leake B, McCaffrey DF, Paulus HE, Brook RH, Shekelle PG: Quality of care for patients with rheumatoid arthritis. JAMA 2000, 284(8):984-992.
15. Malhan S, Pay S, Ataman S, Dalkilic E, Dinc A, Erken E, Ertenli I, Ertugrul E, Gogus F, Hamuryudan V, Inanc M, Karaarslan Y, Karadag O, Karakoc Y, Keskin G, Kisacik B, Kiraz S, Oksel F, Oksuz E, Pirildar T, Sari I, Soy M, Senturk T, Taylan A: The cost of care of rheumatoid arthritis and ankylosing spondylitis patients in tertiary care rheumatology units in Turkey. Clin Exp Rheumatol 2012, 30(2):202-207.
16. Reginster JY: The prevalence and burden of arthritis. Rheumatology 2002, 41(Suppl. 1):S3-S6.
17. Guillemin F, Durieux S, Daures JP, Lafuma A, Saraux A, Sibilia J, Bourgeois P, Sany J: Costs of rheumatoid arthritis in France: a multicenter study of 1109 patients managed by hospital-based rheumatologists. J Rheumatol 2004, 31(7):1297-1304.
18. Verstappen S, Verkleij H, Bijlsma JW, Buskens E, Kruize AA, Heurkens AH, Van Der Veen MJ, Jacobs JW: Determinants of direct costs in Dutch rheumatoid arthritis patients. Ann Rheum Dis 2004, 63(7):817-824
19. Westhovens R, Boonen A, Verbruggen L, et al: Healthcare consumption and direct costs of rheumatoid arthritis in Belgium. Clin Rheumatol 2005, 24(6):615-619.
20. Malhan S, Akbulut LA, Bodur H, Tulunay CF: Annual costs of rheumatoid arthritis in Turkey. Rheumatol Int 2010, 30(5):637-641
21. Ting G, Schneeweiss S, Katz JN, Weinblatt ME, Cabral D, Scranton RE, Solomon DH: Performance of a rheumatoid arthritis records-based index of severity. J Rheumatol 2005, 32(9):1679-1687.
22. Cabral D, Katz JN, Weinblatt ME, Ting G, Avorn J, Solomon DH: Development and assessment of indicators of rheumatoid arthritis severity: results of a Delphi panel. Arthritis Rheum 2005, 53(1):61-66.
23. Baser O, Du J, Xie L, Wang H, Dysinger AH, Wang L: Derivation of severity index for rheumatoid arthritis and its association with health care outcomes. J Med Econ 2012, 15(5):918-924.
24. Elixhauser A, Steiner C, Harris D, Coffey R: Comorbidity measures for use with administrative data. Med Care 1998, 36(1):8-27
25. Manning WG, Basu A, Mullahy J: Generalized modeling approaches to risk adjustment of skewed outcomes data. J Health Econ 2005, 24(3)465-488
26. Manning WG, Mullahy J: Estimating log models: to transform or not to transform? J Health Econ 2001, 20(4)461-494.
27. Rossi PH, Freeman HE, Lipsey MW: Evaluation: A systematic approach. Sage Publications, Incorporated; 2003.
28. Wooldridge JM: Econometric analysis of cross section and panel data. Cambridge: Mass: MIT Press; 2002.
29. Baser O: Too much ado about instrumental variable approach: is the cure worse than the disease? Value Health 2009, 12(8):1201-1209. doi:10.1111/ j.1524-4733.2009.00567.x. Epub 2009 May 29. http://www.ispor.org/publications/value/editorial.asp Value in Health is published by ISPOR, Lawrenceville, NJ.